We are a computational pathology company applying its proprietary AI technologies to analyze whole slide images based on spatial analytics. Our mission is to develop tools that will improve the accuracy and efficiency of pathologists and to generate predictive data to optimize patient outcomes. Co-founded by a group of leading pathologists, computer scientists, and biotechnologists, SpIntellx is committed to generating real-world evidence based on spatial analytics for pathology and biopharma companies.
SpIntellx, which leverages AI for digital pathology markets, closes seed financing and launches company.
PITTSBURGH, PA (September 10, 2018) – SpIntellx, Inc., a computational pathology company, today announced the recent closing of a seed financing round led by Newlin Investment Company, an early-stage venture capital firm. Read more…
Chakra Chennubhotla, Ph.D.
S. Chakra Chennubhotla, Ph.D., Co-Founder and President–SpIntellx, is currently an Associate Professor in the Department of Computational and Systems Biology at the University of Pittsburgh. Dr Chennubhotla leads the campus-wide effort in computational systems pathology at Pitt, with active participation of collaborators from both academia and industry. His group's primary research focus is in building machine learning and systems biology algorithms to discover the mechanistic basis of disease progression (metastasis) from in-situ imaging data. Chakra moved from industry to academia to pursue his Ph.D. at the University of Toronto in the Department of Computer Science, specializing in computer vision and machine learning for high-dimensional perceptual data.
D. Lansing Taylor, Ph.D.
Dr. Taylor is currently the Director of the University of Pittsburgh Drug Discovery Institute managing the collaborative programs involving clinicians, biomedical scientists, chemists, engineers and computer scientists / systems biologists at Pitt, Carnegie Mellon University, the University of Pittsburgh Medical Center (UPMC), as well as external collaborators from academia, Federal Agencies and industry. Previously, Lans was Co-Founder and CEO of Cellomics Inc., which developed and commercialized High Content Screening (HCS) that permitted single cell quantitation of multiplexed fluorescence biomarkers in arrays of cells and tissues. In addition to Cellomics, Dr. Taylor co-founded several other biotech companies, such as Biological Detection Systems, Inc. and Cernostics, Inc., and is an expert in multiplexed fluorescence and biomarker imaging.
Michael Becich M.D., Ph.D.
Dr. Becich is currently the Chairman of the University of Pittsburgh Department of Biomedical Informatics. He co-founded the Association for Pathology Informatics and was the inaugural course director of the Pathology Informatics Summit. He is Associate Vice-Chancellor for Informatics for the Health Sciences and co-directs the Center for Commercial Applications of Healthcare Data as part of the Pittsburgh Health Data Alliance in partnership with UPMC Enterprises. Previously, Mike was co-founder of Tissue Informatics and InterScope Technologies. He has been an innovator in bioinformatics, imaging and tissue banking informatics and data sharing. Dr. Becich is currently consultant to several academic health systems, cancer centers and biotech companies.
Jeffrey Fine, M.D.
Dr. Fine is a breast and gynecologic pathologist at the University of Pittsburgh, where he is Associate Professor of Pathology and Director of the Advanced Imaging and Image Analysis subdivision (Pathology Informatics). He maintains a busy clinical schedule at UPMC Magee Womens Hospital, with expertise in image analysis, whole slide imaging, telepathology, in vivo/ex vivo microscopy (IVM/EVM) and computational pathology. Dr. Fine has fellowship training in Pathology Informatics, including a Certificate in Biomedical Informatics (University of Pittsburgh). He is AP/CP board certified (residency at Cleveland Clinic) and earned his M.D. at Ohio State University.